Cholesterol-Lowering drug may boost lung cancer immunotherapy
NCT ID NCT07061535
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 2 trial tests whether adding tafolecimab (a cholesterol-lowering drug) to standard chemotherapy and the immunotherapy sintilimab helps people with extensive-stage small cell lung cancer live longer without their cancer growing. About 40 adults who have not had prior treatment for this advanced lung cancer will receive all three drugs together. The study measures how long the cancer stays under control and how well patients respond.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- sintilimab, tafolecimab, etoposide, carboplatin or cisplatin
- What this could lead to
- If successful, this combination could offer a new first-line treatment option that improves how long people with extensive-stage small cell lung cancer live without their disease worsening.
- What could go wrong
- This is an early-phase, single-arm trial with only 40 participants, so results may not apply broadly. Adding tafolecimab to standard therapy may increase side effects without clear benefit.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for EXTENSIVE DISEASE SMALL CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Department of Thoracic Medical Oncology, Zhejiang Cancer Hospital, Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences
RECRUITINGHangzhou, Zhejiang, China
-
First Affiliated Hospital, School of Medicine, Zhejiang University
RECRUITINGHangzhou, Zhejiang, China
-
Hunan Cancer Hospital/the Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University
NOT_YET_RECRUITINGChangsha, Hunan, China
-
Second Affiliated Hospital, School of Medicine, Zhejiang University
RECRUITINGHangzhou, Zhejiang, China
-
Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Science
RECRUITINGJinan, Shandong, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a pill help keep advanced lung cancer at bay?
- Can a Two-Drug attack shrink tough lung cancers?
- Could adding chemo to tarlatamab overcome resistance in lung cancer?
- Can a smartphone app ease the burden of advanced lung cancer?
- Lung cancer drug tislelizumab under Real-World scrutiny in 440-Patient european study
- New combo shows promise for tough lung cancer